共 77 条
[1]
Gilhus NE(2016)Myasthenia gravis. Longo DL, editor The New England Journal of Medicine 375 2570-2581
[2]
Farmakidis C(2018)Treatment of myasthenia gravis Neurologic Clinics 36 311-337
[3]
Pasnoor M(2016)International consensus guidance for management of myasthenia gravis: Executive summary Neurology. 87 419-425
[4]
Dimachkie MM(2019)Italian recommendations for the diagnosis and treatment of myasthenia gravis Neurological Sciences 40 1111-1124
[5]
Barohn RJ(2020)Immunosuppressive and immunomodulatory therapies for neuromuscular diseases. Part II: New and novel agents Muscle & Nerve 61 17-25
[6]
Sanders DB(2000)Myasthenia gravis: Recommendations for clinical research standards Neurology. 55 16-23
[7]
Wolfe GI(2017)Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review Neurology. 89 1069-1077
[8]
Benatar M(2018)Lifestyle factors and disease-specific differences in subgroups of Swedish myasthenia gravis Acta Neurologica Scandinavica 138 557-565
[9]
Evoli A(2016)Factors affecting outcome in myasthenia gravis: Outcome in myasthenia gravis Muscle & Nerve 54 1041-1049
[10]
Gilhus NE(2015)Treatment of myasthenia gravis in patients with elderly onset at advanced age Japan Clinical Medicine 6 JCM.S29601-195